NDAINJECTIONINJECTABLEPriority Review
Approved
Nov 1959
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
Priority Review
LYOPHILIZED CYTOXAN (cyclophosphamide) by Baxter is alkylating activity [moa]. Approved for iv of the ann arbor staging system), hodgkin's disease, lymphocytic lymphoma (nodular and 12 more indications. First approved in 1959.
Drug data last refreshed 4d ago
Mechanism of Action
Alkylating Activity
Worked on LYOPHILIZED CYTOXAN at Baxter? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.